96 Tests PN: C194402

Components:

1x Ab-conjugated beads (premixed). PN: C194402A. One bottle containing 4.7 mL of the following AimPlex antibody-bead conjugates:

  • S4P5 - anti-human IGF I

  • S5P8 - anti-human IGF II

2x Biotin-detection Ab(premixed). PN: C194402B. One vial containing 1.25 mL of the following biotinylated antibodies.

  • Biotin - anti-human IGF I

  • Biotin - anti-human IGF II

2x NR dAb Diluent. PN: 07NDX21. One vial containing 1.25 mL of biotin detection antibody diluent.

Lyophilized Standard Mix- Human IGF I and IGF II, 2-Plex. PN: HG19402. One vial containing lyophilized recombinant IGF I and IGF II. 

      Standard Info Sheet: Indicates reconstitute volume and standard concentrations.

Basic Kit for Premixed Panels: 

  • 1x Streptavidin-PE (SAPE). PN: 07SP0011. One bottle containing 2;5 mL of 1x SAPE.

  • 10x Reading Buffer. PN: 07RB1. One bottle containing 4 mL of 10x buffer.

  • 10x Wash Buffer. PN: 07WB1. One vial containing 15 mL of 10x buffer.

  • PCR 8-tube Strip. PN: 07P8T1. 2 strips.

  • Filter Plate and Lid. PN: 07FPL1. 1 96- well filter plate and 1 plate lid.

  • Plate Seals. PN: 07PSR1. 4 sealers.

Application Optimal antibody pairs and antigen standards for assaying human IGF I and IGF II.  To be used in conjunction with the AimPlex Basic Kit for Premixed Panels (PN: U100005) and the IGF I/IGF II Diluent Kit (PN: P910102, universal for all sample types). Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure. 

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

Note: Some sample types such as serum and plasma should be pretreated to release IGF I and IGF II from their binding proteins for accurate measurement.  There are a number of sample pretreatment methods described in literature including size exclusion chromatography, solid-phase extraction and acid-ethanol extraction.  The acid-ethanol extraction method described by Breier et al. (J Endocrinol. 1991, 128:347-357) has been used in many published studies.  The appropriate specimen pretreatment method should be determined by the investigator according to the sample type and experimental conditions. 

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LODs): IGF I, < 5 pg/mL; IGF II, < 5 pg/mL.

  • LLOQs: IGF I, < 10 pg/mL; IGF II, < 10 pg/mL.

  • ULOQs: IGF I, > 20,000 pg/mL; IGF II, > 20,000 pg/mL.

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity:

    • IGF I: Negligible cross-reactivity with IGF II at 10,000pg/mL.

    • IGF II: < 1% cross-reactivity with IGF I at 10,000pg/mL

  • Sample volume: 15 µL/test 

For Research Use Only.  Not for use in diagnostic procedures.

Description IGF I

Insulin-like growth factor 1 (IGF-1), also called somatomedin C, is a protein that in humans is encoded by the IGF1 gene.[1][2] IGF-1 has also been referred to as a "sulfation factor" and its effects were termed "nonsuppressible insulin-like activity" (NSILA) in the 1970s. IGF-1 is a hormone similar in molecular structure to insulin. It plays an important role in childhood growth and continues to have anabolic effects in adults. A synthetic analog of IGF-1, mecasermin, is used for the treatment of growth failure.

References:

  1. Höppener JW, de Pagter-Holthuizen P, Geurts van Kessel AH, Jansen M, Kittur SD, Antonarakis SE, Lips CJ, Sussenbach JS (1985). "The human gene encoding insulin-like growth factor I is located on chromosome 12". Hum. Genet. 69 (2): 157–60. doi:10.1007/BF00293288. PMID 2982726.

  2. Jansen M, van Schaik FM, Ricker AT, Bullock B, Woods DE, Gabbay KH, Nussbaum AL, Sussenbach JS, Van den Brande JL (1983). "Sequence of cDNA encoding human insulin-like growth factor I precursor". Nature 306 (5943): 609–11. doi:10.1038/306609a0. PMID 6358902.

  3. Salmon WD, Daughaday WH (1957). "A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro". J Lab Clin Med 49 (6): 825–36. PMID 13429201.

  4. Keating GM (2008). "Mecasermin". BioDrugs 22 (3): 177–88. doi:10.2165/00063030-200822030-00004. PMID 18481900.

Description IGF II

Insulin-like growth factor 2 (IGF-2) is one of three protein hormones that share structural similarity to insulin. IGF2 is a well-characterized neutral peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like and mitogenic activities. The growth factor has a major, but not absolute, dependence on somatotropin. It is believed to be a major fetal growth factor in contrast to Insulin-like growth factor 1, which is a major growth factor in adults. The major role of IGF-2 is as a growth promoting hormone during gestation. IGF-2 exerts its effects by binding to the IGF-1 receptor. IGF2 may also bind to the IGF-2 receptor (also called the cation-independent mannose 6-phosphate receptor), which acts as a signaling antagonist; that is, to prevent IGF2 responses.

References:

  1. Pham NV, Nguyen MT, Hu JF, Vu TH, Hoffman AR (Nov 1998). "Dissociation of IGF2 and H19 imprinting in human brain". Brain Research 810 (1-2): 1–8. doi:10.1016/s0006-8993(98)00783-5. PMID 9813220.

  2. Chen DY, Stern SA, Garcia-Osta A, Saunier-Rebori B, Pollonini G, Bambah-Mukku D, Blitzer RD, Alberini CM (Jan 2011). "A critical role for IGF-II in memory consolidation and enhancement". Nature 469 (7331): 491–7. doi:10.1038/nature09667. PMID 21270887.

  3. Balduyck B, Lauwers P, Govaert K, Hendriks J, De Maeseneer M, Van Schil P (Jul 2006). "Solitary fibrous tumor of the pleura with associated hypoglycemia: Doege-Potter syndrome: a case report". Journal of Thoracic Oncology 1 (6): 588–90. doi:10.1097/01243894-200607000-00016. PMID 17409923.